A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
A phase 3 trial of Asciminib and Nilotinib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) is a phase 3 interventional study registered as NCT05456191 by Novartis Pharmaceuticals, with 568 participants enrolled, started 2022-11-21 and due to reach its primary completion in 2025-05-15. Interventions recorded: Asciminib and Nilotinib. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialAsciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialOpen-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialA Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Shares Nilotinib, Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialSafety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Shares Asciminib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialA Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.